CBAY News and Press, CymaBay Therapeutics Inc. From 05/15/23

2023-05-15 22:52:02 ET CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Conference Call May 15, 2023, 16:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Officer Charles McWherter - Chief Scientific Officer...

2023-05-15 16:07:31 ET CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q1 GAAP EPS of -$0.29 misses by $0.19 . Held $236.4 million in cash, cash equivalents and investments as of March 31, 2023. We believe that cash and investments on hand are sufficient to fund C...

Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in patients with PBC published in Hepatology Completed a public ...

2023-05-14 17:35:54 ET Major earnings expected after the bell on Monday include: Danaos Corporation ( DAC ) Canoo ( GOEV ) Arrival ( ARVL ) Cara Therapeutics ( CARA ) Fortuna Silver Mines ( FSM ) For further details see: Notable earnings a...

2023-05-14 17:35:00 ET CymaBay Therapeutics ( NASDAQ: CBAY ) is scheduled to announce Q1 earnings results on Monday, May 15th, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $19.54M Over the last 3 months, EPS estimates h...

2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webc...

2023-05-09 14:45:20 ET Summary Today, we shine the spotlight on CymaBay Therapeutics, Inc., whose stock has had a big rally in 2023. The company is advancing its lead asset Seladelpar towards approval and recently signed a licensing deal in Japan, but cash burn remains a concern. ...

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.08% on the day to $10.3. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chro...

2023-05-09 08:19:46 ET Summary I present additional information about my methodology for finding the best stocks. Some of the technical tools I use to make final decisions to buy or sell. The leadership of certain stocks and sectors changes occasionally, and we can take this i...